Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

By M. Manco-Johnson, Thomas C Abshire, A. Shapiro, B. Riske, Michele R. Hacker, R. Kilcoyne, J. D. Ingram, M. Manco-Johnson, S. Funk, L. Jacobson and 19 more. New England Journal of Medicine, 2007

1,755 citations recorded by the source corpus.

Subfields: Biochemistry, Hematology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/837d4467ea610bff9686f3ab21b8934ee5e4c715

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. High
2. F. Mingozzi
3. J. Mendell
4. Lindsey A. George
5. S. Al-Zaidy
6. L. Rodino-Klapac
7. Kimberly Goodspeed
8. S. Gray

Citations in the corpus

• Guidelines for the management of hemophilia (2013, background): “A dental evaluation is advisable before initiating long-term bisphosphonate therapy [28,29].”
• Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges (2011, background): “The disease is currently treated by intravenous infusion of clotting factor concentrate”
• Current Clinical Applications of In Vivo Gene Therapy with AAVs (2020, methodology): “replacement therapy (ERT) delivered prophylactically to prevent or on demand for bleeding.(172,173) Although effective, ERT is limited by an approximately 40% noncompliance rate, costs R$200,000 annually, and advances arthropathy.”